Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 593

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial

Inman, Robert D., Davis, John C., Heijde, Désirée Van Der, Diekman, Laura, Sieper, Joachim, Kim, Sung Il, Mack, Michael, Han, John, Visvanathan, Sudha, Xu, Zhenhua, Hsu, Benjamin, Beutler, Anna, Braun, Jürgen·2008·Arthritis & Rheumatism

Abstract

Objective: To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GO‐RAISE study. Methods: Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score ≥4, and a back pain score of ≥4 were randomly assigned in a 1.8:1.8:1 ratio to receive subcutaneous injections of golimumab (50 mg or 100 mg) or placebo every 4 weeks. The primary end point was the proportion of patients with at least 20% improvement in the ASsessment in AS (ASAS20) criteria at week 14. Results: At randomization, 138, 140, and 78 patients were assigned to the 50‐mg, 100‐mg, and placebo groups, respectively. After 14 weeks, 59.4%, 60.0%, and 21.8% of patients, respectively, were ASAS20 responders ( P < 0.001). A 40% improvement in the ASAS criteria at week 24 occurred in 43.5%, 54.3%, and 15.4% of patients, respectively. Patients receiving golimumab also showed significant improvement in the physical and mental component summary scores of the Short Form 36 Health Survey, the Jenkins Sleep Evaluation Questionnaire score, the BASDAI score, and the Bath AS Functional Index score, but not the Bath AS Metrology Index score. Through week 24, 85.6% of golimumab‐treated patients and 76.6% of patients in the placebo group had ≥1 adverse event, and 5.4% and 6.5% of patients, respectively, had ≥1 serious adverse event. Eight golimumab‐treated patients and 1 placebo‐treated patient had markedly abnormal liver enzyme values (≥100% increase from baseline and a value >150 IU/liter), which were transient. Conclusion: Golimumab was effective and well tolerated in a large cohort of patients with AS during a 24‐week study period.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.23969

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 593

Metadata

Authors
Inman, R. D., Davis, J. C., Heijde, D. V. D., Diekman, L., Sieper, J., Kim, S. I., Mack, M., Han, J., Visvanathan, S., Xu, Z., Hsu, B., Beutler, A., & Braun, J.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2008-10-30
Volume
58
Issue
11
Pages
3402-3412
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2092773063
Cited by
593
References
18
FWCI
20.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial. https://app.cochat.ai/papers/10.1002/art.23969
The paper
Inman, R. D., Davis, J. C., Heijde, D. V. D., Diekman, L., Sieper, J., Kim, S. I., Mack, M., Han, J., Visvanathan, S., Xu, Z., Hsu, B., Beutler, A., & Braun, J. (2008). Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.23969

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.